Phase 2 trial of monoamine oxidase inhibitor phenelzine in biochemical recurrent prostate cancer.
Mitchell Eric GrossDavid B AgusTanya B DorffJacek K PinskiDavid I QuinnOlga CastellanosPatrick GilmoreJean C ShihPublished in: Prostate cancer and prostatic diseases (2020)
Phenelzine demonstrated efficacy in patients with biochemical recurrent castrate-sensitive prostate cancer. Most treatment-related toxicities were mild, but rare significant and reversible cardiovascular toxicities were observed. Therapies directed at MAOA may represent a new avenue for treatment in patients with recurrent prostate cancer.